Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, discusses optimization of therapy for patients with HER2-positive metastatic breast cancer. Dr Authal shares her experience with toxicity management, dose escalation, and incorporation of neratinib into her practice.
More Videos in Metastatic Breast Cancer Content Hub
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Part 1 – Case Presentation Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A.…
In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from…
Part 2 – Case Discussion Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A.…
Tufia C. Haddad, MD, an oncologist at Mayo Clinic, Rochester, Minnesota, discusses what to expect before, during, and after initial treatment for metastatic breast cancer. Dr Haddad emphasizes…
Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
Javier Cortés, MD, PhD, head of the International Breast Cancer Centre (IBCC), Barcelona, Spain, reviews subgroup analyses from the Phase 3 EMERALD trial. Professor Cortés discusses how these…
Aditya Bardia, MD, MPH, director of translational research integration, UCLA, explains how metastatic estrogen receptor-positive breast cancers can develop ESR1 mutations. Donald McDonnell, PhD, research scientist, Duke University,…
Barbara Pistilli, MD, chair of the breast cancer unit, Gustave Roussy, Villejuif, France, provides a case-based discussion of therapeutic options for a patient with pretreated HR+/HER2- (IHC 0)…
